PolyNovo Future Growth

Future criteria checks 6/6

PolyNovo is forecast to grow earnings and revenue by 49.3% and 20.5% per annum respectively. EPS is expected to grow by 49.1% per annum. Return on equity is forecast to be 22.2% in 3 years.

Key information

49.3%

Earnings growth rate

49.1%

EPS growth rate

Medical Equipment earnings growth	16.7%
Revenue growth rate	20.5%
Future return on equity	22.2%
Analyst coverage	Good
Last updated	28 Feb 2024

Recent future growth updates

Recent updates

When Should You Buy PolyNovo Limited (ASX:PNV)?

Feb 28

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Feb 02

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

These Analysts Think PolyNovo Limited's (ASX:PNV) Earnings Are Under Threat

Jan 14

Breakeven Is Near for PolyNovo Limited (ASX:PNV)

Dec 28

Earnings and Revenue Growth Forecasts

ASX:PNV - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	167	24	8	23	7
6/30/2025	133	13	-4	12	8
6/30/2024	103	4	0	2	8
12/31/2023	83	2	-6	-3	N/A
9/30/2023	75	-2	-7	-5	N/A
6/30/2023	66	-5	-8	-7	N/A
3/31/2023	59	-6	-5	-4	N/A
12/31/2022	53	-7	-2	-2	N/A
9/30/2022	48	-4	-2	-2	N/A
6/30/2022	42	-1	-3	-2	N/A
3/31/2022	38	0	-3	-2	N/A
12/31/2021	35	1	-4	-2	N/A
9/30/2021	32	-2	-4	-1	N/A
6/30/2021	29	-5	-4	0	N/A
3/31/2021	27	-5	-6	0	N/A
12/31/2020	25	-5	-7	0	N/A
9/30/2020	24	-5	-8	0	N/A
6/30/2020	22	-4	-9	0	N/A
3/31/2020	20	-4	-11	-2	N/A
12/31/2019	18	-4	-13	-3	N/A
9/30/2019	16	-3	-11	-3	N/A
6/30/2019	14	-3	-10	-3	N/A
3/31/2019	12	-4	-8	-5	N/A
12/31/2018	9	-5	-7	-6	N/A
9/30/2018	8	-5	-7	-7	N/A
6/30/2018	7	-6	-7	-7	N/A
3/31/2018	6	-6	-7	-7	N/A
12/31/2017	5	-6	-7	-7	N/A
9/30/2017	4	-6	N/A	-6	N/A
6/30/2017	4	-5	N/A	-5	N/A
3/31/2017	4	-4	N/A	-4	N/A
12/31/2016	5	-3	N/A	-3	N/A
9/30/2016	4	-3	N/A	-3	N/A
6/30/2016	3	-3	N/A	-4	N/A
3/31/2016	2	-3	N/A	-4	N/A
12/31/2015	0	-2	N/A	-4	N/A
9/30/2015	0	-2	N/A	-3	N/A
6/30/2015	0	-1	N/A	-3	N/A
3/31/2015	0	-2	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-3	N/A
3/31/2014	0	-2	N/A	-3	N/A
12/31/2013	0	-2	N/A	-3	N/A
9/30/2013	0	-2	N/A	-2	N/A
6/30/2013	0	-1	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PNV's forecast earnings growth (49.3% per year) is above the savings rate (2.2%).

Earnings vs Market: PNV's earnings (49.3% per year) are forecast to grow faster than the Australian market (13.4% per year).

High Growth Earnings: PNV's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PNV's revenue (20.5% per year) is forecast to grow faster than the Australian market (4.7% per year).

High Growth Revenue: PNV's revenue (20.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PNV's Return on Equity is forecast to be high in 3 years time (22.2%)

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

PolyNovo Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Price target increased by 9.7% to AU$2.14

Price target increased by 7.4% to AU$1.95

Price target decreased by 9.5% to AU$1.88

Price target decreased by 7.8% to AU$2.07

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

Recent updates

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

Independent Non-Executive Chairman recently bought AU$434k worth of stock

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Price target decreased to AU$1.57

Consensus forecasts updated

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Price target decreased to AU$1.70

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to AU$2.04

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Price target decreased to AU$2.48

PolyNovo Limited Provides an Update on its Hernia Device

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

Non-Executive Independent Director recently sold AU$571k worth of stock

Price target increased to AU$2.92